Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.44 |
| ▸ | KIT | P10721 | 5/20 | 0.44 |
| ▸ | CLK1 | P49759 | 3/20 | 0.43 |
| ▸ | CSF1R | P07333 | 1/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29923791 | 1.00 | MTNR1A (0.50) | MTNR1AMTNR1BBRD4DYRK1AKIT | |
| SCHEMBL8320227 | 0.82 | KIT (0.67) | DYRK1AKIT | |
| SCHEMBL13505056 | 0.81 | MTNR1A (0.51) | MTNR1AMTNR1BDYRK1AKITCSF1R | |
| SCHEMBL30287159 | 0.79 | MTNR1A (0.50) | MTNR1AMTNR1BDYRK1AKITCLK1 | |
| SCHEMBL1047222 | 0.79 | MTNR1A (0.50) | MTNR1AMTNR1BDYRK1AKITCSF1R | |
| SCHEMBL25190048 | 0.79 | MTNR1A (0.50) | MTNR1AMTNR1BDYRK1AKITCLK1 | |
| SCHEMBL23625712 | 0.79 | GSK3B (0.51) | MTNR1AMTNR1BDYRK1AKITCSF1R | |
| SCHEMBL30548012 | 0.79 | MTNR1A (0.50) | MTNR1AMTNR1BDYRK1AKITCSF1R | |
| SCHEMBL24032672 | 0.77 | MTNR1A (0.48) | MTNR1AMTNR1BDYRK1AKITCSF1R | |
| SCHEMBL1045946 | 0.77 | BRD4 (0.54) | BRD4DYRK1AKITCLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4055013-B1 | WDR5 INHIBITORS AND MODULATORS | UNIV VANDERBILT (US) | 2024-03-20 | — | — | EP | disclosed |
| US-20230026466-A1 | WDR5 INHIBITORS AND MODULATORS | VANDERBILT UNIVERSITY | 2023-01-26 | — | — | US | disclosed |
| WO-2022140527-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| EP-2496086-B1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2017-05-31 | — | — | EP | disclosed |
| US-9096593-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096593-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096593-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140045840-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140045840-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140045840-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20100035878-A1 | INHIBITORS OF C-JUN N-TERMINAL KINASES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS RELATING TO APOPTOSIS AND/OR INFLAMMATION | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-02-11 | — | — | US | disclosed |
| US-20100035878-A1 | INHIBITORS OF C-JUN N-TERMINAL KINASES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS RELATING TO APOPTOSIS AND/OR INFLAMMATION | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-02-11 | — | — | US | disclosed |
| US-7645769-B2 | Inhibitors of c-Jun N-terminal kinases for the treatment of neurodegenerative disorders relating to apoptosis and/or inflammation | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-01-12 | — | — | US | disclosed |
| US-7645769-B2 | Inhibitors of c-Jun N-terminal kinases for the treatment of neurodegenerative disorders relating to apoptosis and/or inflammation | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-01-12 | — | — | US | disclosed |
| US-7645769-B2 | Inhibitors of c-Jun N-terminal kinases for the treatment of neurodegenerative disorders relating to apoptosis and/or inflammation | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-01-12 | — | — | US | disclosed |
| US-20070072896-A1 | Inhibitors of c-Jun N-terminal kinases for the treatment of neurodegenerative disorders relating to apoptosis and/or inflammation | EISAI CO., LTD. (JP) | 2007-03-29 | — | — | US | disclosed |
| US-20070072896-A1 | Inhibitors of c-Jun N-terminal kinases for the treatment of neurodegenerative disorders relating to apoptosis and/or inflammation | EISAI CO., LTD. (JP) | 2007-03-29 | — | — | US | disclosed |
| US-20070072896-A1 | Inhibitors of c-Jun N-terminal kinases for the treatment of neurodegenerative disorders relating to apoptosis and/or inflammation | EISAI CO., LTD. (JP) | 2007-03-29 | — | — | US | disclosed |
| EP-1749829-A1 | JNK inhibitors | Eisai London Research Laboratories Limited (GB) | 2007-02-07 | — | — | EP | disclosed |
| EP-1749829-A1 | JNK inhibitors | Eisai London Research Laboratories Limited (GB) | 2007-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035878-A1 | INHIBITORS OF C-JUN N-TERMINAL KINASES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS RELATING TO APOPTOSIS AND/OR INFLAMMATION | NFKBIA, CHUK, MAP3K1 | MTNR1A 1487/4885MTNR1B 1439/4885BRD4 1290/4885 |
| US-20230026466-A1 | WDR5 INHIBITORS AND MODULATORS | WDR5, WDR1, WDR3 | MTNR1A 3776/4885MTNR1B 3677/4885BRD4 33/4885 |
| US-20070072896-A1 | Inhibitors of c-Jun N-terminal kinases for the treatment of neurodegenerative disorders relating to apoptosis and/or inflammation | NFKBIA, CHUK, MAP3K1 | MTNR1A 1487/4885MTNR1B 1439/4885BRD4 1290/4885 |
| US-20140045840-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | KIT, FLT3, BRAF | MTNR1A 1804/4885MTNR1B 1352/4885BRD4 3163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.